---
title: "Bone Biologics | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286468418.md"
datetime: "2026-05-14T21:02:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286468418.md)
  - [en](https://longbridge.com/en/news/286468418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286468418.md)
---

# Bone Biologics | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.43, beating the estimate of USD -0.54.

EBIT: As of FY2026 Q1, the actual value is USD -843.86 K.

Bone Biologics Corporation operates in a single segment focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1. The company has not yet generated revenues from its planned operations.

#### Operating Expenses (Three Months Ended March 31)

-   **Research and Development:** Research and development expenses decreased from $423,576 in 2025 to $141,597 in 2026, representing a decrease of $281,979 or -66.57%, primarily due to the timing of clinical trials.
-   **General and Administrative:** General and administrative expenses increased by $48,547, from $614,910 in 2025 to $663,457 in 2026, an increase of 7.89%.
-   **Total Operating Expenses:** Total operating expenses decreased from $1,038,486 in 2025 to $805,054 in 2026, a decrease of $233,432 or -22.48%.

#### Operational Metrics (Three Months Ended March 31)

-   **Loss from Operations:** Loss from operations was - $805,054 in 2026, compared to - $1,038,486 in 2025, a decrease of $233,432 or -22.48%.
-   **Change in Fair Value of Warrant Liability:** The change in fair value of warrant liability was $265 in 2026, compared to $1,355 in 2025, a decrease of $1,090 or -80.44%.
-   **Interest Income:** Interest income increased from $20,039 in 2025 to $38,801 in 2026, an increase of $18,762 or 93.63%.
-   **Net Loss:** Net loss was - $765,988 in 2026, compared to - $1,017,092 in 2025, a decrease of $251,104 or -24.69%.

#### Cash Flow (Three Months Ended March 31)

-   **Net Cash Used in Operating Activities:** Net cash used in operating activities was - $804,282 in 2026, compared to - $926,125 in 2025, with the reduction primarily due to decreased research and development costs.
-   **Net Cash Provided by Financing Activities:** Net cash provided by financing activities was $0 in 2026, compared to $347,549 in 2025, which was from the net proceeds of the At The Market (ATM) Facility.
-   **Cash, End of Period:** Cash at the end of the period was $4,530,040 at March 31, 2026, compared to $5,334,322 at December 31, 2025.

#### Unique Metrics

-   **Stock-Based Compensation:** Stock-based compensation was $23,505 for the three months ended March 31, 2026, compared to $50,605 for the same period in 2025.
-   **Options Issued to Settle Accrued Bonus:** Options issued to settle accrued bonus amounted to $34,854 for the three months ended March 31, 2026, compared to $46,183 for the same period in 2025.
-   **Warrant Liability:** Warrant liability was $438 at March 31, 2026, compared to $703 at December 31, 2025.
-   **UCLA TDG Exclusive License Agreement Payments:** UCLA TDG Exclusive License Agreement Payments were $10,237 for the three months ended March 31, 2026, compared to $10,000 for the same period in 2025.

#### Future Outlook and Strategy

Bone Biologics Corporation continues to focus on bone regeneration with its NELL-1/DBM product, currently in a pilot clinical study in Australia for degenerative disc disease, and anticipates substantial future investment in NELL-1 development for a pivotal clinical study. Operating expenditures for the next twelve months are estimated at $5.4 million, with available cash expected to fund operations into the fourth quarter of 2026. The company plans to seek additional debt or equity financing to support future operations and working capital, though there is no assurance such financing will be obtained on favorable terms.

### Related Stocks

- [BBLG.US](https://longbridge.com/en/quote/BBLG.US.md)

## Related News & Research

- [Bone Biologics extends rhNELL-1 shelf life to 32 months as NB1 spine fusion trial advances](https://longbridge.com/en/news/295662468.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296129742.md)
- [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md)